Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. ADVM-022 is a single, in-office intravitreal injection gene therapy. ADVM-022 is being developed for the treatment of patients with chronic retinal diseases who respond to anti-vascular endothelial growth factor therapy, including wet age-related macular degeneration and diabetic macular edema. ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. We show 31 historical shares outstanding datapoints in our coverage of ADVM's shares outstanding history.
Understanding the changing numbers of ADVM shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADVM versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADVM by allowing them to research ADVM shares outstanding history
as well as any other stock in our coverage universe. |
Free ADVM Email Alerts:
Video: Shares Outstanding Importance
